Adagene Inc.

NASDAQ:ADAG

Biotechnology

Healthcare
$2.01 +3.68%

+$0.13 today

Market cap
$75.67M
Beta
0.59
P/E (TTM)
-7.9
EPS (TTM)
-$0.47
52W Low $1.30High $4.75

Volume 1.18M

Average 0.21M

Returns on capital

Adagene Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-49.8%

avg -25.2%

ROIC

-36.2%

avg -39.4%

ROA

-22.5%

avg -28.8%

Analysis

ROA is currently the strongest return metric at -22.5% versus its period average of -28.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Guizhong Liu

Senior Vice President of Early Drug Discovery—55——

Jiping Zha

Executive Vice President of Clinical Development————

Yan Li

Senior Vice President of Bioinformatics & Information Technology—51——

Mickael Chane-Du

Chief Strategy Officer————

Qinghai Zhao

Chief Manufacturing Officer—651.25K<0.01%

Chunfang Gu

Executive Director of Finance——0<0.01%

Alexander Goergen

Vice President & Head of Business Development—39——

Ling Zhou

Executive Director & Head of Human Resources——1.25K<0.01%

Xiaohong She

Senior Vice President & Head of Clinical Operations—59——

Man Kin Tam

Chief Financial Officer & Director—4912.00K0.03%

Peter Luo

Co- Founder, Chairman, Chief Executive Officer and President of R&D—6088.53K0.24%

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 30, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

5

$162,244.33

Sells

0

$0.00

Net Transaction Value

+$162,244.33

Net buying

Most Active

Luo Peter

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 23, 26

Tam Man Kin

Direct

Buy$6K
Sep 16, 26

Luo Peter

Direct

Buy$64K
Aug 14, 26

DO CUONG V

Direct

Buy$7.5K
Aug 5, 26

Luo Peter

Direct

Buy$1K
Aug 4, 26

Luo Peter

Direct

Buy$83.7K

Summary

Insiders reported 5 buys worth $162,244.33 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $162,244.33. Luo Peter was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-6.2%
+4.1% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at -6.2% over three years. Forward estimates point to Revenue at +4.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Adagene Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ADAG's management, answered from reported figures.

Who manages ADAG?

Adagene Inc. (ADAG) lists 11 active executives. The top listed executive is Guizhong Liu, Senior Vice President of Early Drug Discovery.

Are ADAG insiders buying or selling?

Recent insider activity shows net buying of $402,244.33.